Drugs / GSK3772701
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07670377 | Jun → Aug 2026 | Plasmodium falciparum malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07545681 | Jul 2026 → Jul 2027 expected | Plasmodium falciparum malaria | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3772701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07670377 ↗ |
| Route | Oral | “administered orally” NCT07545681 ↗ |
| Target | CYP3A4 | “determine whether GSK3772701 acts as an inducer and/or inhibitor of CYP3A4” NCT07670377 ↗ |